Increased tirzepatide use for glycemic and weight control since United States market entry
1. In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval in the United States ...
Tag: Type 2 Diabetes Mellitus
Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared ...
Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin
1. In this multi-database retrospective cohort study, rosuvastatin was found to be associated with slightly decreased risk of all-cause mortality ...
#VisualAbstract: Insulin Efsitora is Noninferior to Degludec in Type 2 Diabetes without Previous Insulin Treatment
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Semaglutide Improves Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
High dose aflibercept reduced treatment burden in patients with diabetic macular edema
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
The 2 Minute Medicine Podcast Episode 38
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
Superior long-term outcomes of bariatric surgery compared to medical and lifestyle management for patients with type 2 diabetes and obesity
1. After 7- and 12-year follow-ups, there was superior glycemic control after bariatric surgery for the management of type 2 ...
High-dose oral semaglutide effectively glycemic control in patients with type 2 diabetes mellitus
1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. ...
Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in ...